Generate Biomedicines Valuation Estimate
Generate Biomedicines Valuation as of Last Funding Round
Generate Biomedicines Company Overview
Generate Biomedicines is a pioneering therapeutics company at the forefront of generative biology, machine learning, and biological engineering. Using their innovative Generate Platform, they have revolutionized the way medicines are created by expanding the breadth of technical possibilities. This breakthrough in generative biology represents a fundamental shift in drug discovery, allowing Generate Biomedicines to generate medicines on demand across multiple therapeutic modalities with unprecedented speed and success rates. With a dedicated team and state-of-the-art facilities, they are building the future of medicine.
Generate Biomedicines Valuation History
FAQ
Does Generate Biomedicines have stock?
Yes, Generate Biomedicines and almost all privately held companies issue stock so founders, employees, and investors can participate in equity ownership. However, because Generate Biomedicines is privately held, it is more challenging to acquire shares than if the company was publicly traded.
Is Generate Biomedicines publicly traded?
No, Generate Biomedicines is a privately held company. It is not publicly traded or offered directly on any stock exchange like the NYSE, Nasdaq, etc.
Who owns Generate Biomedicines stock?
As a privately held company, Generate Biomedicines shares are held by its founders, management, employees, venture capital funds, or other private individuals and institutional investors.
Disclosure rules differ for private and public companies, so it may not always be possible to know the complete ownership (cap table) of a private company like Generate Biomedicines.
What is the stock symbol for Generate Biomedicines?
Generate Biomedicines is a privately held company. Therefore, it does not have a stock symbol or “ticker” that trades on public exchanges like the NYSE, Nasdaq, etc.
Can I buy Generate Biomedicines stock on UpMarket?
If you would like to buy shares in Generate Biomedicines, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Generate Biomedicines stock availability. Note: inquiries are non-binding, subject to market availability, and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Generate Biomedicines as well.
What is Generate Biomedicines stock price?
The stock price of Generate Biomedicines can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
For illustrative purposes, however, assuming Generate Biomedicines has issued 250 million shares, at the estimated UpMarket valuation of $2.18 billion, each share of Generate Biomedicines stock would be worth $8.71.
How do Generate Biomedicines pre-IPO trades work?
Pre-IPO trades for Generate Biomedicines will typically involve accredited investors purchasing shares from current shareholders through specialized investment platforms like UpMarket. Trades generally occur on the secondary market, meaning Generate Biomedicines doesn't issue new shares or receive capital–shares are privately exchanged between two parties.
While investors aim to profit from a potential IPO or acquisition, these investments carry high risks due to limited liquidity and information. Understanding all terms and conditions is crucial, as each transaction can have unique characteristics. Investing in private companies can be extremely risky and may result in significant capital loss.
When is Generate Biomedicines going to go public?
The decision to go public through an Initial Public Offering (IPO) is complex and depends on various factors, including the company's financial performance, market conditions, and strategic goals.
Unless Generate Biomedicines officially announces its intention to go public, any predictions about when or if it will do so would be speculative.
Investors interested in Generate Biomedicines should monitor official company communications and reliable financial news sources for any updates regarding potential IPO plans.
How do I exit my investment if I invest in Generate Biomedicines with UpMarket?
Exiting your investment in Generate Biomedicines typically involves one of these scenarios: 1) selling your shares on a secondary market to other interested investors; 2) holding shares until a liquidity event occurs, such as the company going public (IPO) or being acquired.
Investors must know that the timing and availability of these exit options are inherently unpredictable, and there is no guarantee of when or if they will occur.
How can I sell Generate Biomedicines shares?
If you own Generate Biomedicines shares, you may be able to find a buyer on a pre-IPO marketplace or via an introduction by a registered broker-dealer like UpMarket. It is important to note that the class of shares you own may impact your ability to sell. For example, shares issued to startup employees often have transaction limitations, including lock-up periods and a right of first refusal by the company, which may prevent you from selling your shares freely.
How does UpMarket estimate the valuation of Generate Biomedicines?
UpMarket’s valuation estimate for Generate Biomedicines is algorithmically generated based on recent primary round financings by Generate Biomedicines, market conditions, company popularity, sector performance, and public market comps.
It is important to note that UpMarket’s valuation estimate for Generate Biomedicines could be outdated, may not reflect all recent news or market events, and is not intended to inform any investment decision-making. UpMarket’s valuation estimate is not meant to be a warranty or projection of potential financial returns or company performance. Valuations can change rapidly and unexpectedly.
Why choose UpMarket?
UpMarket was founded in 2019 and has helped hundreds of investors access alternative investments. UpMarket is a licensed broker-dealer based in the United States. UpMarket customers have invested over $150 million in pre-IPO companies, hedge funds, private equity, real estate, and other alternatives.
If you are an accredited investor, you can create a free account to access our deal flow and opportunities. There is never any pressure to invest.
UpMarket clients have invested in companies like
Generate Biomedicines,
SpaceX, Neuralink, Anthropic, and many others. UpMarket and its leadership have been mentioned in media outlets like Forbes, WealthManagement, Wealth and Finance News, and TechBullion.
Generate Biomedicines Management
| Name | Position |
|---|---|
| Michael Nally | CEO |
| Jason Silvers | CFO |
| Gevorg Grigoryan Ph.D | CTO |
